scholarly journals Brivanib Alaninate

2020 ◽  
Author(s):  
Keyword(s):  
Brivanib Alaninate

Brivanib alaninate inhibited dengue virus proliferation through VEGFR2/AMPK pathway

2021 ◽  
pp. 105721
Author(s):  
Yihong Wan ◽  
Wenyu Wu ◽  
Yuanda Wan ◽  
Jiawen Zhang ◽  
Liren Li ◽  
...  
Keyword(s):  
Dengue Virus ◽  
Ampk Pathway ◽  
Brivanib Alaninate

Discovery and Validation of Biomarkers that Respond to Treatment with Brivanib Alaninate, a Small-Molecule VEGFR-2/FGFR-1 Antagonist

2007 ◽  
Vol 67 (14) ◽  
pp. 6899-6906 ◽  
Author(s):  
Mark Ayers ◽  
Joseph Fargnoli ◽  
Anne Lewin ◽  
Qiuyan Wu ◽  
J. Suso Platero
Keyword(s):  
Small Molecule ◽  
Brivanib Alaninate

429 POSTER Phase 1 study of food effects on pharmacokinetics of brivanib alaninate in patients with advanced or metastatic solid tumors

2008 ◽  
Vol 6 (12) ◽  
pp. 135 ◽  
Author(s):  
H. Hurwitz ◽  
P. LoRusso ◽  
G.I. Shapiro ◽  
A. Wolanksi ◽  
J. Chemidlin ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Phase 1 ◽  
Food Effects ◽  
Phase 1 Study ◽  
Brivanib Alaninate

scholarly journals Treatment with Brivanib alaninate as a second-line monotherapy after Sorafenib failure in hepatocellular carcinoma

Medicine ◽  
2019 ◽  
Vol 98 (10) ◽  
pp. e14823 ◽  
Author(s):  
Hong Zhu ◽  
Chunyan Zhang ◽  
Xi Yang ◽  
Cheng Yi
Keyword(s):  
Hepatocellular Carcinoma ◽  
Second Line ◽  
Brivanib Alaninate

Analysis of plasma biomarkers potentially associated with antiangiogenic resistance in NCIC CTG/AGITG CO.20: A phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, k-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC).

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 3572-3572
Author(s):  
Jeremy David Shapiro ◽  
Lillian L. Siu ◽  
Christopher J O'Callaghan ◽  
John Raymond Zalcberg ◽  
Malcolm J. Moore ◽  
...  
Keyword(s):  
Overall Survival ◽  
Colorectal Carcinoma ◽  
Randomized Trial ◽  
Phase Iii ◽  
Plasma Samples ◽  
Wild Type ◽  
Metastatic Colorectal Carcinoma ◽  
Plasma Biomarkers ◽  
Anti Vegf ◽  
Brivanib Alaninate

3572 Notice of Retraction: "Analysis of plasma biomarkers potentially associated with antiangiogenic resistance in NCIC CTG/AGITG CO.20: A phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, k-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC)." Abstract 3572, published in the 2012 Annual Meeting Proceedings Part I, a supplement to the Journal of Clinical Oncology, has been retracted by Jeremy Shapiro, MBBS, and Lillian Siu, MD, on behalf of the NCIC, AGITG, and all authors of the abstract. The authors have been unable to finalize their data presentation due to the complexity of the analysis, and difficulties with the statistical interpretation of the significance of several possible predictive biomarkers. Background: In the CO.20 trial, the addition of BRIV, a tyrosine kinase inhibitor targeting vascular endothelial and fibroblast growth factor receptors (VEGFR2,3 and FGFR 1,2,3), to CET, increased objective response rate and progression free survival, but did not significantly increase overall survival. Previous clinical studies demonstrated modulation of circulating angiogenic factors (CAF) in CRC which occur on therapy or upon progression (Kopetz JCO 2010). Methods: CO.20 pts were randomized 1:1 to CET plus either BRIV (Arm A) or placebo (ARM B) in a double-blind design. Pts may have had 1 prior anti-VEGF based therapy, but no prior anti-EGFR therapy. Primary endpoint was overall survival (OS). Baseline pre-treatment plasma samples were analyzed using commercial Multi-Analyte ELISAs to measure CAF, immunologic, and growth factors, with an initial discovery and subsequent validation data set. Results: 750 pts were randomized (376 in Arm A and 374 in Arm B). Median OS in the intent-to-treat population was 8.8 months in Arm A and 8.1 months in Arm B, hazard ratio (HR)=0.88; 95%CI=0.74-1.03; p=0.12. In an exploratory subgroup analysis, there is a statistically non-significant trend favoring the effect of brivanib on OS among the 41% pts who received prior anti-VEGF therapy versus those who did not.Baseline plasma samples were collected from 96% of pts, and analysis is ongoing. Results of the largest circulating biomarker analysis will be presented. CAF results will be compared with response and survival data to look for potential patient subgroups that may benefit more from the combination treatment. Conclusions: This large scale analysis will provide insights on the potential use of CAF or CAF profiles as predictive markers in CRC.

Integrated Application of Quality-by-Design Principles to Drug Product Development: A Case Study of Brivanib Alaninate Film–Coated Tablets

2016 ◽  
Vol 105 (1) ◽  
pp. 168-181 ◽  
Author(s):  
Sherif I.F. Badawy ◽  
Ajit S. Narang ◽  
Keirnan R. LaMarche ◽  
Ganeshkumar A. Subramanian ◽  
Sailesh A. Varia ◽  
...  
Keyword(s):  
Product Development ◽  
Quality By Design ◽  
Drug Product ◽  
Design Principles ◽  
Brivanib Alaninate
Sign in / Sign up

Export Citation Format

Share Document